BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 11969236)

  • 1. Positron emission tomography in colorectal cancer.
    Flamen P
    Best Pract Res Clin Gastroenterol; 2002 Apr; 16(2):237-51. PubMed ID: 11969236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Evaluation of positron emission tomography by using F-18-fluorodeoxyglucose in diagnosis of recurrent colorectal cancer].
    Kula Z; Szefer J; Zuchora Z; Romanowicz G; Pietrzak T
    Pol Merkur Lekarski; 2004; 17 Suppl 1():63-6. PubMed ID: 15603351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PET and PET-CT for evaluation of colorectal carcinoma.
    Delbeke D; Martin WH
    Semin Nucl Med; 2004 Jul; 34(3):209-23. PubMed ID: 15202102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of FDG-PET on the management algorithm for recurrent colorectal cancer.
    Arulampalam T; Costa D; Visvikis D; Boulos P; Taylor I; Ell P
    Eur J Nucl Med; 2001 Dec; 28(12):1758-65. PubMed ID: 11734912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FDG-PET in colorectal cancer.
    de Geus-Oei LF; Ruers TJ; Punt CJ; Leer JW; Corstens FH; Oyen WJ
    Cancer Imaging; 2006 Oct; 6(Spec No A):S71-81. PubMed ID: 17114081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of 18F-fluoro-deoxy-glucose positron emission tomography (FDG-PET) in the management of patients with colorectal cancer.
    Pelosi E; Deandreis D
    Eur J Surg Oncol; 2007 Feb; 33(1):1-6. PubMed ID: 17126522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FDG PET and PET/CT for colorectal cancer.
    Delbeke D; Martin WH
    Methods Mol Biol; 2011; 727():77-103. PubMed ID: 21331930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [18F-fluorodeoxyglucose positron emission tomography in colorectal cancer: value in primary staging and follow-up].
    Jörg L; Heinisch M; Rechberger E; Kurz F; Klug R; Aufschnaiter M; Hammer J; Langsteger W
    Acta Med Austriaca; 2002; 29(5):176-9. PubMed ID: 12506769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Fluorodeoxyglucose PET/Computed Tomography on the Management of Patients with Colorectal Cancer.
    Laurens ST; Oyen WJ
    PET Clin; 2015 Jul; 10(3):345-60. PubMed ID: 26099671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [F-18 fluorodeoxyglucose positron emission tomography in colorectal carcinoma].
    Jörg L; Langsteger W
    Wien Med Wochenschr; 2002; 152(11-12):276-9. PubMed ID: 12138655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Positron emission tomography and colorectal carcinoma: an update.
    Tzimas GN; Koumanis DJ; Meterissian S
    J Am Coll Surg; 2004 Apr; 198(4):645-52. PubMed ID: 15051018
    [No Abstract]   [Full Text] [Related]  

  • 12. Role of FDG-PET in the diagnosis and treatment of colorectal liver metastases.
    Wiering B; Ruers TJ; Oyen WJ
    Expert Rev Anticancer Ther; 2004 Aug; 4(4):607-13. PubMed ID: 15270664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ovarian cancer recurrence: role of whole-body positron emission tomography using 2-[fluorine-18]-fluoro-2-deoxy- D-glucose.
    Torizuka T; Nobezawa S; Kanno T; Futatsubashi M; Yoshikawa E; Okada H; Takekuma M; Maeda M; Ouchi Y
    Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):797-803. PubMed ID: 12029554
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FDG-PET improves the staging and selection of patients with recurrent colorectal cancer.
    Lonneux M; Reffad AM; Detry R; Kartheuser A; Gigot JF; Pauwels S
    Eur J Nucl Med Mol Imaging; 2002 Jul; 29(7):915-21. PubMed ID: 12111132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Positron emission tomography and colorectal cancer.
    Arulampalam TH; Costa DC; Loizidou M; Visvikis D; Ell PJ; Taylor I
    Br J Surg; 2001 Feb; 88(2):176-89. PubMed ID: 11167864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinical application of positron emission tomography to colorectal cancer management.
    Arulampalam TH; Costa DC; Bomanji JB; Ell PJ
    Q J Nucl Med; 2001 Sep; 45(3):215-30. PubMed ID: 11788814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical impact of 18F-FDG-PET in the suspicion of recurrent colorectal cancer based on asymptomatically elevated serum level of carcinoembryonic antigen (CEA) in Taiwan.
    Shen YY; Liang JA; Chen YK; Tsai CY; Kao CH
    Hepatogastroenterology; 2006; 53(69):348-50. PubMed ID: 16795969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Established, emerging and future roles of PET/CT in the management of colorectal cancer.
    Herbertson RA; Scarsbrook AF; Lee ST; Tebbutt N; Scott AM
    Clin Radiol; 2009 Mar; 64(3):225-37. PubMed ID: 19185652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [18F]Fluorodeoxyglucose PET/Computed Tomography in Gastrointestinal Malignancies.
    Donswijk ML; Hess S; Mulders T; Lam MG
    PET Clin; 2014 Oct; 9(4):421-41, v-vi. PubMed ID: 26050945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of positron emission tomography in the management of recurrent colorectal cancer: a review.
    Watson AJ; Lolohea S; Robertson GM; Frizelle FA
    Dis Colon Rectum; 2007 Jan; 50(1):102-14. PubMed ID: 17115340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.